Canley Vale (AU)
{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
Nearby (Liverpool, Australia, +144 more cities)
facility
Liverpool Hospital ( Site 4006)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
Nearby (Liverpool, Australia, +199 more cities)
facility
Liverpool Hospital ( Site 0226)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
city
Nearby (Liverpool, Australia, +127 more cities)
facility
Liverpool Hospital
biomarker
BRAF V600E
condition
Colorectal Carcinoma
drug
cetuximab, +3 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
Nearby (Liverpool, Australia, +92 more cities)
facility
Liverpool Hospital ( Site 0220)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
Nearby (Liverpool, Australia, +105 more cities)
facility
Liverpool Hospital ( Site 0055)
condition
Colorectal Adenocarcinoma
drug
bevacizumab, +1 more drug
drug type
targeted therapy
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
Nearby (Liverpool, Australia, +141 more cities)
facility
GSK Investigational Site
condition
Multiple Myeloma
drug
belantamab mafodotin
drug type
chemotherapy, +1 more type
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
Nearby (Liverpool, Australia, +197 more cities)
facility
Liverpool Hospital /ID# 215415
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
condition
Acute Myeloid Leukemia
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
Nearby (Liverpool, Australia, +156 more cities)
facility
Liverpool Hospital /ID# 202431
biomarker
IGH-CCND1 Fusion, +1 more biomarker
condition
Multiple Myeloma
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
Nearby (Liverpool, Australia, +165 more cities)
facility
Liverpool Hospital /ID# 221803
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
navitoclax, +1 more drug
drug type
targeted therapy